Jonathan Kaufman

Jonathan Kaufman has an extensive and varied background in the business world, with a focus on biotechnology investments and Urban Robotics. Jonathan is currently the CEO of Lipella Pharmaceuticals, a position they have held since 2018. Prior to this, they were a board member for LEMUR: League of Electronic Musical Urban Robots from 2012 to 2015, and a partner and CSO for LaunchCyte LLC from 2000 to 2004. Jonathan has also served on the board of MetriTrack Inc. from 2014 to 2017, and Semprus BioSciences Corp. from 2007 to 2012. In addition to their work in the private sector, Jonathan Kaufman has also interned at the University of Pennsylvania Center for Technology Transfer from 1999 to 2000, and worked as a consultant for SmithKline Beecham Corporation in 1998. Jonathan began their career as a programmer/analyst for Merck from 1989 to 1992.

Jonathan Kaufman holds an MBA from The Wharton School, a PhD in Biophysics from the University of Pennsylvania School of Medicine, and MS degrees in Geophysics and Measurement and Control from Brown University and Carnegie Mellon University, respectively. Jonathan also holds a BS in Physics from Carnegie Mellon University. In addition, Jonathan Kaufman is certified by the Financial Industry Regulatory Authority (FINRA) in Series 7, Series 63, and Series 79.

Allison Houck - Director, Finance, Janet Okonski - Director, Clinical Operations, and Michael Chancellor - Chief Medical Officer report to Jonathan Kaufman.